|drug1821||Lopinavir/Ritonavir 400 mg/100 mg Wiki||1.00|
|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Prophylactic treatment in cancer patients undergoing antineoplastic therapy during the COVID-19 pandemic.
Description: assessed by positive polymerase chain reaction (PCR) from routine nasal swabs (performed every 28 days)Measure: Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections Time: 12 weeks after initiation of therapy
Description: defined as combined endpoint of hospitalization rate or deathMeasure: Number of severe COVID-19 cases Time: 12 weeks after initiation of therapy
Description: grading as outlined by the world health organization (WHO)Measure: Severity of COVID-19 cases Time: 12 weeks after initiation of therapy
Description: significant clinical and laboratory abnormalities according to CTCAE criteriaMeasure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: 12 weeks after initiation of therapy
Description: other than COVID-19Measure: Number of viral and bacterial infections Time: 12 weeks after initiation of therapy
Description: Development of azithromycin-resistant bacterial strains as assessed by nasal swabs testMeasure: Number of participants with azithromycin-resistant bacterial strains in nasal swabs test Time: 12 weeks after initiation of therapy
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports